Mon Sep 09 14:20:00 UTC 2024: ## Dupixent’s Dominance in Atopic Dermatitis Market Challenged by New Treatments

**EXTON, PA – September 9, 2024** – Since its introduction in 2017, Sanofi/Regeneron’s Dupixent has been the dominant treatment for atopic dermatitis (AD) in the US market. However, a new wave of treatments, including LEO Pharma’s Adbry, Pfizer’s Cibinqo, and AbbVie’s Rinvoq, are starting to erode Dupixent’s market share.

While Dupixent still holds the largest share, its dominance is diminishing with the rising adoption of these newer therapies. This trend is expected to continue as even more treatment options emerge.

According to Spherix Global Insights, a leading market research firm, Adbry has seen significant growth since its launch, and now competes closely with Rinvoq, whose usage has plateaued. Despite the competition, the overall demand for effective AD treatments remains high, as evidenced by a rising number of adult patients receiving advanced systemic therapies.

Spherix research indicates that dermatologists are increasingly prioritizing treatments that effectively reduce itch, alongside unique mechanisms of action. Upcoming therapies, such as Galderma’s nemolizumab and Eli Lilly’s lebrikizumab, are poised to further shake up the market.

Dermatologists have shown a preference for nemolizumab, which targets IL-31, over lebrikizumab, which targets IL-13, and anticipate adopting both treatments at the expense of Dupixent.

“The atopic dermatitis market is evolving rapidly,” said [Name of Spherix spokesperson], [Title]. “Manufacturers need to differentiate their products by focusing on specific efficacy attributes like itch reduction and unique mechanisms of action.”

Spherix continues to monitor the atopic dermatitis market, providing valuable insights to stakeholders through its RealTime Dynamix™ service. This service delivers quarterly or semiannual reports, offering unbiased analysis of the competitive landscape and valuable insights into the market trends.

Read More